Sicart Associates LLC Ionis Pharmaceuticals Inc Transaction History

Sicart Associates LLC

$272 Million
Q3 2024

A detailed history of Sicart Associates LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Sicart Associates LLC holds 191,523 shares of IONS stock, worth $7 Million. This represents 2.82% of its overall portfolio holdings.

Number of Shares

191,523

Previous 191,523 -0.0%

Holding current value

$7 Million

Previous $9.13 Million 15.94%

% of portfolio

2.82%

Previous 3.66%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	SELL	$36.45 - $47.7 $90,031 - $117,819	-2,470 Reduced 1.27%	191,523 $9.13 Million
Q1 2024 May 02, 2024	SELL	$42.03 - $53.55 $12,609 - $16,065	-300 Reduced 0.15%	193,993 $8.41 Million
Q4 2023 Jan 19, 2024	SELL	$43.39 - $51.63 $383,524 - $456,357	-8,839 Reduced 4.35%	194,293 $9.83 Million
Q3 2023 Oct 25, 2023	SELL	$38.5 - $47.13 $69,877 - $85,540	-1,815 Reduced 0.89%	203,132 $9.21 Million
Q2 2023 Jul 28, 2023	SELL	$34.73 - $43.33 $199,732 - $249,190	-5,751 Reduced 2.73%	204,947 $8.41 Million
Q1 2023 May 09, 2023	SELL	$33.58 - $41.2 $1.19 Million - $1.47 Million	-35,560 Reduced 14.44%	210,698 $7.53 Million
Q4 2022 Jan 27, 2023	SELL	$37.12 - $46.52 $286,492 - $359,041	-7,718 Reduced 3.04%	246,258 $0
Q3 2022 Nov 01, 2022	SELL	$36.54 - $48.66 $1.27 Million - $1.69 Million	-34,775 Reduced 12.04%	253,976 $11.2 Million
Q2 2022 Aug 05, 2022	SELL	$31.71 - $43.0 $508,343 - $689,333	-16,031 Reduced 5.26%	288,751 $10.7 Million
Q1 2022 May 06, 2022	BUY	$29.88 - $37.04 $664,859 - $824,177	22,251 Added 7.88%	304,782 $11.3 Million
Q4 2021 Jan 31, 2022	SELL	$25.61 - $35.1 $223,396 - $306,177	-8,723 Reduced 2.99%	282,531 $8.63 Million
Q3 2021 Oct 22, 2021	SELL	$33.54 - $40.55 $2.59 Million - $3.13 Million	-77,155 Reduced 20.94%	291,254 $9.77 Million
Q2 2021 Jul 23, 2021	SELL	$34.54 - $47.25 $65,246 - $89,255	-1,889 Reduced 0.51%	368,409 $14.7 Million
Q1 2021 May 10, 2021	SELL	$42.51 - $63.78 $1.39 Million - $2.08 Million	-32,610 Reduced 8.09%	370,298 $16.6 Million
Q4 2020 Jan 22, 2021	SELL	$45.3 - $60.27 $697,031 - $927,374	-15,387 Reduced 3.68%	402,908 $22.8 Million
Q3 2020 Oct 14, 2020	SELL	$47.45 - $62.95 $51,103 - $67,797	-1,077 Reduced 0.26%	418,295 $19.8 Million
Q2 2020 Jul 30, 2020	SELL	$46.85 - $61.05 $486,303 - $633,699	-10,380 Reduced 2.42%	419,372 $24.7 Million
Q1 2020 Apr 22, 2020	BUY	$41.6 - $63.4 $787,904 - $1.2 Million	18,940 Added 4.61%	429,752 $20.3 Million
Q4 2019 Jan 30, 2020	BUY	$53.85 - $65.27 $14,808 - $17,949	275 Added 0.07%	410,812 $24.8 Million
Q3 2019 Oct 21, 2019	SELL	$59.06 - $72.15 $167,435 - $204,545	-2,835 Reduced 0.69%	410,537 $24.6 Million
Q2 2019 Jul 23, 2019	SELL	$62.09 - $86.14 $224,331 - $311,223	-3,613 Reduced 0.87%	413,372 $26.6 Million
Q1 2019 May 01, 2019	SELL	$52.92 - $81.17 $5.56 Million - $8.52 Million	-104,974 Reduced 20.11%	416,985 $33.8 Million
Q4 2018 Jan 22, 2019	SELL	$43.37 - $59.54 $81,752 - $112,232	-1,885 Reduced 0.36%	521,959 $28.2 Million
Q3 2018 Oct 19, 2018	SELL	$42.88 - $53.7 $2,144 - $2,685	-50 Reduced 0.01%	523,844 $27 Million
Q2 2018 Jul 19, 2018	BUY	$40.53 - $50.7 $7.18 Million - $8.98 Million	177,082 Added 51.06%	523,894 $21.8 Million
Q1 2018 Apr 12, 2018	SELL	$44.08 - $55.05 $2.26 Million - $2.82 Million	-51,260 Reduced 12.88%	346,812 $15.3 Million
Q4 2017 Jan 17, 2018	BUY	$50.3 - $64.39 $455,215 - $582,729	9,050 Added 2.33%	398,072 $20 Million
Q3 2017 Nov 06, 2017	BUY	$45.56 - $59.57 $17.7 Million - $23.2 Million	389,022	389,022 $19.7 Million

Others Institutions Holding IONS

# of Institutions

402

Shares Held

136M

Call Options Held

862K

Put Options Held

582K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.19B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sicart Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sicart Associates LLC with notifications on news.

Account

Sicart Associates LLC Ionis Pharmaceuticals Inc Transaction History